Press Releases
Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by oxidative stress, today announced that a clinical trial site has been added to its Phase 1/2 clinical trial evaluating NPI-002, a proprietary antioxidant molecule delivered via a sustained release intravitreal implant, for the delay of cataract progression in patients undergoing vitrectomy. Read more...
Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by oxidative stress, today announced that target enrollment of 48 patients has been reached in the SLO-RP Phase 1/2 clinical trial of NPI-001 tablets in patients with retinitis pigmentosa (RP) associated with Usher syndrome (USH). Read more...
Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts, and other ocular diseases caused by oxidative stress, today announced the appointment of Russell Kelley, Ph.D., MBA, to its board of directors. Dr. Kelley currently serves as managing director of the Retinal Degeneration (RD) Fund, the venture arm of Foundation Fighting Blindness and a significant investor of Nacuity. Read more...
Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by oxidative stress, and Arctic Therapeutics International, a precision-based drug development and diagnostic testing company using genetic and genealogy information to guide therapeutic development, today announced the companies have entered into an exclusive licensing agreement and strategic partnership for the development and commercialization of NPI-001 in Iceland for the treatment of hereditary cystatin C amyloid angiopathy (HCCAA). Read more...
Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other ocular diseases caused by oxidative stress, today announced the closing of a $16.5 million Series B financing led by Foundation Fighting Blindness and its venture arm RD Fund. Additional existing investors also participated in the round. Maxim Merchant Capital, a division of Maxim Group LLC, served as sole placement agent for the financing. Read more...
Nacuity Pharmaceuticals, Inc. (Nacuity) today announced the expansion of its Scientific Advisory Board (SAB) with the appointment of Nancy Holekamp, M.D., and Richard L. Lindstrom, M.D. Read more...
January 18, 2017
Press Release: "Foundation Fighting Blindness Supporting Clinical Development of NACA, Promising New Drug for Many Forms of RP"
News
August 24, 2021
"New Trial for Usher Syndrome Vision Loss"
September 27, 2017
"FFB’s Investments Are Filling the Pipeline for Vision-Saving Therapies"
January 19, 2017
"Foundation Investing in Drug to Slow Many Forms of RP"
Publications
Martis RM, Grey AC, Wu H, Wall GM, Donaldson PJ, Lim JC. N-Acetylcysteine amide (NACA) and diNACA inhibit H2O2-induced cataract formation ex vivo in pig and rat lenses. Exp Eye Res. 2023 Sep;234:109610. doi: 10.1016/j.exer.2023.109610. Epub 2023 Aug 1. PMID: 37536438.
Hector E, Cairns D, Michael Wall G. Evaluation of NACA and diNACA in human cystinosis fibroblast cell cultures as potential treatments for cystinosis. Orphanet J Rare Dis. 2022 Jun 16;17(1):231. doi: 10.1186/s13023-022-02367-w. PMID: 35710564.